CRISPR THERAPEUTICS AG (CRSP) Forecast, Price Target & Analyst Ratings

NASDAQ:CRSP • CH0334081137

Current stock price

57.99 USD
+2.27 (+4.07%)
At close:
58.01 USD
+0.02 (+0.03%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CRISPR THERAPEUTICS AG (CRSP).

Forecast Snapshot

Consensus Price Target

Price Target
$82.88
+ 42.92% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 11, 2026
Period
Q1 / 2026
EPS Estimate
-$1.25
Revenue Estimate
2.754M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
77.14%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$82.88
Upside
+ 42.92%
From current price of $57.99 to mean target of $82.88, Based on 35 analyst forecasts
Low
$33.33
Median
$79.56
High
$305.55

Price Target Revisions

1 Month
-1.66%
3 Months
14.57%

Price Target Summary

35 Wall Street analysts provided a forecast for the next 12 months for CRSP. The average price target is 82.88 USD. This implies a price increase of 42.92% is expected in the next year compared to the current price of 57.99.
The average price target has been revised upward by 14.57% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

CRSP Current Analyst RatingCRSP Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8 10

Analyst Ratings History

CRSP Historical Analyst RatingsCRSP Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 10 20 30

Analyst Ratings Consensus

ChartMill Buy Consensus
77.14%
CRSP was analyzed by 35 analysts. The buy percentage consensus is at 77. So analysts seem to be have mildly positive about CRSP.
In the previous month the buy percentage consensus was at a similar level.
CRSP was analyzed by 35 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-17Piper SandlerReiterate Overweight -> Overweight
2026-02-17Chardan CapitalMaintains Buy -> Buy
2026-02-13TD CowenMaintains Hold -> Hold
2026-02-13NeedhamMaintains Buy -> Buy
2026-02-13Evercore ISI GroupMaintains Outperform -> Outperform
2026-01-30CitizensMaintains Market Outperform -> Market Outperform
2025-12-23CitizensReiterate Market Outperform -> Market Outperform
2025-12-23NeedhamReiterate Buy -> Buy
2025-11-26Chardan CapitalMaintains Buy -> Buy
2025-11-12CitigroupMaintains Buy -> Buy
2025-11-11RBC CapitalMaintains Sector Perform -> Sector Perform
2025-11-11BairdMaintains Neutral -> Neutral
2025-11-10NeedhamMaintains Buy -> Buy
2025-10-17B of A SecuritiesMaintains Buy -> Buy
2025-10-10NeedhamReiterate Buy -> Buy
2025-09-23HC Wainwright & Co.Reiterate Buy -> Buy
2025-09-18JP MorganInitiate Overweight
2025-08-07HC Wainwright & Co.Maintains Buy -> Buy
2025-08-06BarclaysMaintains Equal-Weight -> Equal-Weight
2025-08-05Chardan CapitalMaintains Buy -> Buy
2025-08-05RBC CapitalMaintains Sector Perform -> Sector Perform
2025-07-22B of A SecuritiesMaintains Buy -> Buy
2025-07-08NeedhamReiterate Buy -> Buy
2025-06-27Clear StreetDowngrade Buy -> Hold
2025-06-27JMP SecuritiesReiterate Market Outperform -> Market Outperform

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 11, 2026
Period
Q1 / 2026
EPS Estimate
-$1.25
Revenue Estimate
2.754M
Revenue Q2Q
218.38%
EPS Q2Q
20.96%
Number of Analysts
24

Next Earnings Revisions

Revenue (1 Month)
47.83%
Revenue (3 Months)
11.32%
EPS (1 Month)
0.14%
EPS (3 Months)
-11.31%

Next Earnings Summary

CRSP is expected to report earnings on 5/11/2026. The consensus EPS estimate for the next earnings is -1.25 USD and the consensus revenue estimate is 2.75M USD.
The next earnings revenue estimate has been revised upward by 11.32% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
CRSP revenue by date.CRSP revenue by date.
371.206M
30,833.83%		37.314M
-89.95%		3.51M
-90.59%		31.861M
807.72%		86.829M
172.52%		604.26M
595.92%		2.399B
297.01%		6.085B
153.65%		1.182B
-80.58%		1.569B
32.74%		1.868B
19.06%
EBITDA
YoY % growth
CRSP ebitda by date.CRSP ebitda by date.
-202.701M
68.77%		-447.307M
-120.67%		-548.839M
-22.70%		-472.956M
13.83%		-449.386M
4.98%		-333.509M
25.79%		258.36M
177.47%		463.08M
79.24%		569.16M
22.91%		1.132B
98.89%		1.607B
41.96%
EBIT
YoY % growth
CRSP ebit by date.CRSP ebit by date.
-222.538M
66.94%		-466.566M
-109.66%		-568.318M
-21.81%		-528.915M
6.93%		-500.476M
5.38%		-233.008M
53.44%		-117.153M
49.72%		90.751M
177.46%		432.74M
376.84%		761.33M
75.93%		1.012B
32.93%
Operating Margin
CRSP operating margin by date.CRSP operating margin by date.
-59.95%-1,250.38%-16,191.40%-1,660.07%-576.39%-38.56%-4.88%1.49%36.61%48.52%54.18%
EPS
YoY % growth
CRSP eps by date.CRSP eps by date.
-1.96
76.58%		-4.37
-122.96%		-5.41
-23.80%		-5.02
7.21%		-4.15
17.38%		-2.07
50.03%		-0.99
52.04%		1.04
205.13%		4.42
323.42%		7.32
65.38%		9.55
30.53%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		-1.25
20.96%		-1.24
3.82%		-1.19
-1.40%		-1.18
13.78%		-0.96
23.09%		-0.95
23.41%		-0.88
25.63%		-0.89
24.87%
Revenue
Q2Q % growth		2.754M
218.38%		5.326M
497.09%		7.519M
745.78%		10.304M
1,092.59%		13.923M
405.56%		17.901M
236.11%		28.637M
280.86%		33.346M
223.62%
EBITDA
Q2Q % growth		-115.785M
19.42%		-109M
11.87%		-107.216M
9.32%		-103.333M
23.62%		N/AN/AN/AN/A
EBIT
Q2Q % growth		-139.844M
5.78%		-141.37M
-6.24%		-136.885M
-3.65%		-135.313M
12.57%		-121.908M
12.83%		-121.467M
14.08%		-114.231M
16.55%		-115.3M
14.79%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

CRSP Yearly Revenue VS EstimatesCRSP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
CRSP Yearly EPS VS EstimatesCRSP Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
17.37%
EPS Next 5 Year
17.01%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
333.00%
Revenue Next 5 Year
282.39%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
13.56%
EBIT Next 5 Year
22.37%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

CRISPR THERAPEUTICS AG / CRSP Forecast FAQ

Can you provide the average price target for CRISPR THERAPEUTICS AG stock?

35 analysts have analysed CRSP and the average price target is 82.88 USD. This implies a price increase of 42.92% is expected in the next year compared to the current price of 57.99.

What is the next earnings date for CRSP stock?

CRISPR THERAPEUTICS AG (CRSP) will report earnings on 2026-05-11.

What are the consensus estimates for CRISPR THERAPEUTICS AG (CRSP) next earnings?

The consensus EPS estimate for the next earnings of CRISPR THERAPEUTICS AG (CRSP) is -1.25 USD and the consensus revenue estimate is 2.75M USD.

What is the expected long term growth rate for CRSP stock?

The expected long term growth rate for CRISPR THERAPEUTICS AG (CRSP) is 333%.